Left Menu
Development News Edition

EU governments ban malaria drug for COVID-19, trial paused as safety fears grow

Reuters | Updated: 28-05-2020 00:30 IST | Created: 27-05-2020 23:41 IST
EU governments ban malaria drug for COVID-19, trial paused as safety fears grow

European governments moved on Wednesday to halt the use of anti-malaria drug hydroxychloroquine to treat COVID-19 patients, and a second global trial of it was suspended, further blows to hopes for a treatment promoted by U.S. President Donald Trump.

The moves by France, Italy, and Belgium followed a World Health Organization decision on Monday to pause a large trial of hydroxychloroquine due to safety concerns. A UK regulator said on Wednesday that a separate trial was also being put on hold, less than a week after its launch. The study, being led by the University of Oxford and partly funded by the Bill and Melinda Gates Foundation, was expected to involve as many as 40,000 healthcare workers.

"All hydroxychloroquine trials in COVID-19 remain under close review" while investigators assess any further risks, the Medicines and Healthcare products Regulatory Agency (MHRA) said in an email to Reuters. The swift moves by authorities in countries hit hardest by the pandemic highlighted the challenge for governments scrambling to find ways to treat patients and control the novel coronavirus.

After early reports that it might help some patients, regulators in several countries had allowed hydroxychloroquine to be used as a potential COVID-19 treatment. Trump was a particularly strong supporter, describing the drug as a "gamechanger" and announcing he was taking it to prevent infection.

However, more recent studies have raised serious safety issues. British medical journal The Lancet has reported coronavirus patients receiving hydroxychloroquine were more likely to die and experience dangerous irregular heartbeats. On Wednesday, France's health ministry canceled a decree in place for nearly two months that had allowed hospital doctors to dispense it in specific situations for COVID-19.

Medicines agencies in France and Italy said the drug should not be used for COVID-19 outside clinical trials. Belgium's regulator said trials aiming to evaluate the drug should also take potential risks into consideration. Swiss drugmaker Novartis is pushing ahead with its U.S. study involving 440 patients, while French company Sanofi declined to comment on the future of its two trials.

Italian health authorities concluded that the risks, coupled with little evidence hydroxychloroquine was beneficial against COVID-19, merited a ban outside of clinical trials. "New clinical evidence on the use of hydroxychloroquine in subjects with SARS-CoV-2 infection...indicates an increased risk for adverse reactions with little or no benefit," medicines agency AIFA said.

The WHO said a safety panel would evaluate by mid-June the drug's use in its multi-country trial of potential COVID-19 treatments. Germany is looking at The Lancet study and the WHO's decision but has not made any decision about new guidance on hydroxychloroquine, a spokeswoman for its drugs regulator said.


TRENDING

OPINION / BLOG / INTERVIEW

Why COVID-19 is unstoppable in USA despite it being ranked at the top of GHS Index?

Several worst-hit countries such as Italy, France, Spain, the UK, Canada, and Russia have peaked COVID-19 cases in April. Almost all of them have gradually flattened the curve. However, the USA is setting new daily records of infections tha...

COVID-19 seems cooking biggest ever global scam

The increasing number of corruption cases on COVID-19 funds from throughout the world and involvement of high profile persons indicate that the countries cant ignore corruption in their pandemic response programs. This has generated the nee...

Health Management Information Systems lack holistic, integrated, and pandemic resilient character

Being a part of the United Nations system, the World Health Organization WHO deserves its share of rebuke for its alleged failure issue COVID-19 health emergency alerts on appropriate time. However, the pandemic has also exposed loopholes i...

Pride in the time of coronavirus: a welcome move online?

This year is different in many ways not least as celebrations are also taking place against the dramatic backdrop of a global health crisis and a resurgence in grassroots activism following the death of George Floyd in Minneapolis. ...

Videos

Latest News

HIGHLIGHTS-ILO summit on COVID-19 and the world of work

World leaders spoke at a conference on Wednesday organised by the International Labour Organization on COVID-19 and the world of work.Here are highlights GUY RYDER, ILO HEADThe world of work ... has been plunged into unprecedented crisis. G...

INTERVIEW-Chinese gay dating app BlueCity focused on Asia after IPO

Chinas biggest gay dating apps owner BlueCity is focused on expanding in Asia, its founder said on Wednesday after it made its Nasdaq debut despite a U.S. securities regulator warning against investments in Chinese firms. BlueCity, which sa...

SC recalls order allowing sale of BS-IV vehicles post-lockdown, warns against fraud

The Supreme Court Wednesday recalled its March 27 order by which it had allowed the sale of BS-IV vehicles for 10 days across India, except in Delhi-NCR, after lifting of COVID-19 induced lockdown, a directive which will impact registration...

El Salvador murder rate plummets; study says gangs may have informal pact with government

Homicides in El Salvador fell over 50 in President Nayib Bukeles first year in office, with officials citing tougher enforcement, while a study on Wednesday suggests gangs may have eased up on violence and made informal deals with authoriti...

Give Feedback